IM Cannabis to Report Second Quarter 2024 Financial Results on Wednesday, August 14th at 9:00am ET
IM Cannabis to Report Second Quarter 2024 Financial Results on Wednesday, August 14th at 9:00am ET
Link for the to register for the zoom call: TORONTO and GLIL YAM, Israel, Aug. 6, 2024 /PRNewswire/ -- IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the second quarter 2024 ended June 30, 2024, on Wednesday, August 14, 2024, before the market opens.
醫療大麻公司Im Cannabis Corp.（CSE：IMCC）（納斯達克：IMCC）（以下簡稱“公司”、“IMCannabis”或“IMC”）是一家領先的醫療大麻公司，在以色列和德國開展業務。將於2024年8月14日星期三市場開盤前公佈2024年第二季度截至2024年6月30日的運營和財務結果。
The Company will host a zoom web conference on the same day at 9:00am ET to discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register by clicking here. All relevant information will be sent upon registration.
公司將於同一天早上9:00（美東時間）舉行Zoom網絡研討會，討論結果，併爲投資者答疑解惑。我們誠摯地邀請投資者通過點擊此處來註冊。所有相關信息將在註冊後發送。
If you are unable to join us live, a recording of the call will be available on our website at within 24 hours after the call.
如果您無法參加直播，我們會在通話結束後24小時內在我們的網站上提供通話的錄音。
Link for the to register for the zoom call:
Zoom call註冊鏈接：
About IM Cannabis Corp.
關於IM大麻股份有限公司。
IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company has focused its resources to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.
IMC（納斯達克：IMCC）（CSE：IMCC）是一家國際大麻公司，在以色列和德國這兩個最大的醫用大麻市場爲患者提供高檔大麻產品。公司專注於在最有價值的市場，即以色列和德國實現可持續和盈利性增長。公司利用跨國生態系統，通過獨特的數據驅動方法和全球供應鏈來推動。公司始終致力於負責任的增長，並遵守最嚴格的監管環境，努力擴大其商業和品牌實力，成爲全球高質量的大麻企業。
The IMC ecosystem operates in Israel through Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.
IMC生態系統通過Focus Medical Herbs Ltd.在以色列運營，該公司利用多年的專有數據和病人見解向醫療患者進口和分銷大麻。公司還在以色列經營醫療大麻零售藥店、在線平台、分銷中心和物流中心，以確保在整個價值鏈上提供安全交付和質量控制IMC產品。在德國，IMC生態系統通過Adjupharm GmbH運營，向大麻藥房分銷大麻，爲醫用大麻患者提供幫助。
Company Contact:
Anna Taranko, Director Investor & Public Relations
IM Cannabis Corp.
+49 157 80554338
[email protected]
公司聯繫人：
Anna Taranko，投資和公共關係主任
IM Cannabis Corp.
+49 157 80554338
[email protected]
Oren Shuster, CEO
IM Cannabis Corp.
+972-77-3603504
[email protected]
Oren Shuster，首席執行官
IM Cannabis Corp.
+972-77-3603504
[email protected]
Logo -
標誌 -
SOURCE IM Cannabis Corp.
來源：IM大麻股份有限公司。
